Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Merck & Co., Inc. (MRK) vs Micron Technology, Inc. (MU) Price & Performance

Merck & Co., Inc.Trade
Micron Technology, Inc.Trade

Price performance (Past 24H)

Key statistics

Merck & Co., Inc. vs Micron Technology, Inc. — how do they compare? Merck & Co., Inc. trades at $131.3 (market cap $321.77B), while Micron Technology, Inc. trades at $923.63 (market cap $980.90B). The key difference: Micron Technology, Inc. is far larger — about 3× Merck & Co., Inc.'s market cap, and Merck & Co., Inc. pays the higher dividend (2.61%). Which is the better fit depends on your goals.

MRKMU
Market Cap
$321.77B$980.90B
Sector
HealthTechnology
52-Week High
$131.84$1.21K
52-Week Low
$77.60$115.79
Enterprise Value
$368.53B$961.25B
Dividend Yield
2.61%0.06%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Merck & Co., Inc.

Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.

The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.

Micron Technology, Inc.

Micron Technology (MU) trades at $861.00, down 1.89% amid recent volatility despite strong fundamental performance. The stock shows neutral technical signals with key support at $845 and resistance at $886. Fundamentally, MU demonstrates exceptional profitability with 72.57% gross margins and 55.91% net income margins, supported by three consecutive quarterly earnings beats. Revenue growth accelerated to $37.38 billion in 2025 from $25.1 billion in 2024, with projected 2026 revenue of $90.3 billion indicating robust AI-driven demand.

The outlook remains positive with 81% analyst buy ratings and $1,540 consensus price target representing 79% upside. However, cyclical memory market risks and competitive threats from new entrants like SpaceX's Terrafab facility pose challenges. The stock's current valuation at 19.63 P/E appears reasonable given projected earnings growth, making MU attractive for investors comfortable with semiconductor sector volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK

About Micron Technology, Inc.

Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.

Read more on MU